Shuttle Pharmaceuticals Holdings, Inc. 8-K

What Happened
Shuttle Pharmaceuticals Holdings, Inc. filed an 8-K reporting Amendment No. 1 to the consulting agreement with Number 2 Capital Corp., the entity owned by interim co‑CEO Christopher Cooper. The original consulting agreement was entered March 11, 2025 (previously disclosed March 12, 2025); the amendment is dated January 29, 2026 and extends the agreement’s term effective September 11, 2025 through August 1, 2026.

Key Details

• Consultant: Number 2 Capital Corp., owned by Christopher Cooper (interim co‑CEO).
• Term extension: Amendment effective September 11, 2025; new termination date August 1, 2026.
• Compensation and duties: $20,000 per month; expected to work 40 hours per week; subject to confidentiality and non‑disclosure provisions.
• Termination: Either party may terminate with 30 days’ notice; immediate termination for cause. (Amendment filed as Exhibit 10.1.)

Why It Matters
The filing formalizes and extends the company’s arrangement with its interim co‑CEO, including clear pay, hours, and termination terms. For investors, this confirms management continuity through mid‑2026 and discloses the ongoing cash cost ($20,000/month) of the consulting arrangement.